Global /United States /Healthcare /Drug Manufacturers - General /NKTR

Nektar Therapeutics

NKTR

• NASDAQ: NKTR • Delayed

83.20USD -0.7%

As of 6 June 2026, Nektar Therapeutics has a market cap of $2.81B USD, ranking #5681 globally and #1495 in the United States. It ranks #447 in the Healthcare sector, and #174 in the Drug Manufacturers - General industry.

Global Rank

5681

Country Rank

1495

Sector Rank

447

Industry Rank

174

Key Stats

Market Cap

$2.81BUSD

Enterprise Value

$2.67BUSD

Revenue (TTM)

$55.23MUSD

EBITDA (TTM)

-$129.75MUSD

Net Income (TTM)

-$164.08MUSD

EBITDA Margin

-235%

Profit Margin

-297%

PS Ratio

50.1

PB Ratio

19.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Howard Robin open_in_new

Employees

Founded

1990

IPO

03 May 1994

Website

nektar.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.7%	-11%	21%	132%	37%	97%	634%	637%	-73%

News

NKTR Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	NKTR ISIN: US6402683063 Shares Out.: Shares Outstanding: 33.786M¹ Shares Float: 32.593M² TV: TradingView: NASDAQ: NKTR SA: Stock Analysis: NASDAQ: NKTR YF: Yahoo Finance: NKTR GF: Google Finance: NASDAQ: NKTR NQ: NASDAQ: NKTR BA: Barron's: NKTR MS: Morningstar: XNAS: NKTR	83.20 USD	TV: TradingView: NASDAQ: NKTR SA: Stock Analysis: NASDAQ: NKTR YF: Yahoo Finance: NKTR GF: Google Finance: NASDAQ: NKTR NQ: NASDAQ: NKTR BA: Barron's: NKTR MS: Morningstar: XNAS: NKTR
London Stock Exchange (LSE / LON) MIC: XLON	0UNL ISIN: US6402683063 TV: TradingView: LSE: 0UNL SA: Stock Analysis: LON: 0UNL YF: Yahoo Finance: 0UNL.L GF: Google Finance: LON: 0UNL BA: Barron's: 0UNL MS: Morningstar: XLON: 0UNL	81.99 USD	TV: TradingView: LSE: 0UNL SA: Stock Analysis: LON: 0UNL YF: Yahoo Finance: 0UNL.L GF: Google Finance: LON: 0UNL BA: Barron's: 0UNL MS: Morningstar: XLON: 0UNL
Mexican Bolsa (BMV) MIC: XMEX	NKTR ISIN: US6402683063 TV: TradingView: BMV: NKTR SA: Stock Analysis: BMV: NKTR YF: Yahoo Finance: NKTR.MX GF: Google Finance: BMV: NKTR BA: Barron's: NKTR MS: Morningstar: XMEX: NKTR	1,584.15 MXN	TV: TradingView: BMV: NKTR SA: Stock Analysis: BMV: NKTR YF: Yahoo Finance: NKTR.MX GF: Google Finance: BMV: NKTR BA: Barron's: NKTR MS: Morningstar: XMEX: NKTR

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 27K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 19K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 13K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 10K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 5K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 4K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 11K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 10K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 10K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$182.72B 1.18T DKK 6K%	11.5	Denmark
Sanofi EPA: SAN	$110.65B 95.26B EUR 4K%	19.9	France
GSK plc LSE: GSK	$108.68B 80.96B GBP 4K%	14.6	United Kingdom

chevron_leftBack